TLP
ACRS icon

Tri Locum Partners’s Aclaris Therapeutics ACRS Stock Holding History

Tri Locum Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-55,433
Closed -$806K – 39
2021
Q4 		$806K Buy
+55,433
New +$840K 0.32% 36
2021
Q2 		– Sell
-164,199
Closed -$4.14M – 30
2021
Q1 		$4.14M Buy
+164,199
New +$3.21M 1.03% 19

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Tri Locum Partners's ACRS Position: Q1 2022 in Review

Tri Locum Partners sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 55,433 shares — an estimated $806K sold.

Tri Locum Partners first reported a position in ACRS in Q1 2021 and held it in 2 quarters. The position peaked at $4.14M in Q1 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Tri Locum Partners reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Tri Locum Partners sold 55,433 Aclaris Therapeutics shares in Q1 2022, an estimated $806K.
  • Tri Locum Partners first reported a position in Aclaris Therapeutics in Q1 2021 and held it in 2 quarters.
  • Tri Locum Partners's Aclaris Therapeutics position peaked at $4.14M in Q1 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Tri Locum Partners's 13F filing for Q1 2022, filed 16 May 2022.